Ultragenyx (RARE) Q2 Revenue Up 13%
Ultragenyx Pharmaceutical (NASDAQ:RARE), a rare disease drug developer, reported its second quarter 2025 earnings on August 5, 2025. Both revenue and earnings per share exceeded Wall Street expectations for the period. Revenue reached $166.5 million, topping the analyst estimate of $162.0 million, while net loss per share at $(1.17) was smaller than the expected $(1.30). The quarter showed solid commercial growth across the company’s product range, ongoing improvements in loss figures, and continued investment in its clinical pipeline. Overall, the period demonstrated strong top-line momentum, with total revenue up 13.2% year over year, but also highlighted continued reliance on pipeline advances and persistent net losses.
Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q1 2025 earnings report.
Ultragenyx Pharmaceutical develops and commercializes therapies for rare and ultra-rare genetic diseases. Its focus on these conditions allows it to target patient groups with few treatment options, where competition tends to be lower. The company’s business model centers on in-licensing promising product candidates, building a global commercial presence, and maintaining a diverse clinical pipeline. Its products address a range of rare genetic disorders, with approved therapies and gene therapies for both children and adults.
Source Fool.com
Ultragenyx Pharmaceutical Inc. Stock
The stock is an absolute favorite of our community with 22 Buy predictions and no Sell predictions.
Based on the current price of 28.0 € the target price of 78 € shows a potential of 178.57% for Ultragenyx Pharmaceutical Inc. which would more than double the current price.
